News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OncoMed Pharmaceuticals, Inc. (OMED) Presents Data From The Phase 1b Portion Of The ALPINE Clinical Study Of OMP-59R5 In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium


1/17/2014 9:07:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO, Jan. 17, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the first scientific presentation of results from the Phase 1b portion of its ongoing ALPINE (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety) Phase 1b/2 clinical study of OMP-59R5 (anti-Notch 2/3) in patients with advanced pancreatic cancer. OMP-59R5 is part of OncoMed's collaboration with GlaxoSmithKline (GSK). These data were presented in a poster by Eileen M. O'Reilly, M.D., of Memorial Sloan-Kettering Cancer Center at the 2014 Gastrointestinal Cancers Symposium being held in San Francisco, California.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES